BioCentury | Aug 21, 2020
Product Development

Basket trials carry tumor-agnostic drug development forward

Tumor-agnostic drug development has been slow to catch on, but with wider adoption of gene sequencing and a steady flow of new targeted therapy approvals, companies are starting to re-draw the lines that...
BioCentury | Jun 2, 2020
Product Development

More data needed to determine best use of remdesivir in COVID-19 patients

The latest remdesivir data in moderate COVID-19 patients suggest that the therapy’s Emergency Use Authorization should cover only a five-day course of treatment, which would stretch supplies to treat more patients. But the question remains...
BioCentury | May 6, 2020
Product Development

Phase II data show Novo’s semaglutide leads the pack on NASH resolution

Novo Nordisk disclosed top-line Phase II data in NASH for semaglutide that puts the GLP-1 agonist in pole position with respect to mechanisms addressing NASH resolution. The readout came as Novo Nordisk A/S (CSE:NOVO B;...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

David Eatwell will retire as CFO and EVP of Genmab A/S (CSE:GMAB; NASDAQ:GMAB) on Feb. 29. The cancer antibody therapy company will promote Anthony Pagano, SVP finance and corporate development, to CFO and EVP, effective...
BioCentury | Dec 22, 2018
Product Development

A year of digital progress at Novartis

Novartis AG Chief Digital Officer Bertrand Bodson is capping off his inaugural year with the pharma’s first approval of a digital therapeutic and 10 deals under his belt to integrate new technologies throughout the company....
BioCentury | Sep 21, 2018
Product R&D

China’s rising genomics start-ups

Behind bellwethers BGI Genomics Co. Ltd. and WuXi NextCode Genomics Inc., a new generation of Chinese genomics companies is emerging with ambitions to solve urgent problems, including early cancer detection and clinical trial recruitment, by...
BioCentury | May 1, 2018
Translation in Brief

Rewriting cancer’s origin story

A collection of 29 papers published across a suite of Cell journals in April by The Cancer Genome Atlas (TCGA) consortium completed the Pan-Cancer Atlas -- a comprehensive analysis of molecular signatures across cancer types....
BioCentury | Apr 26, 2018
Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BioCentury | Jan 5, 2018
Politics, Policy & Law

Seeking odd couples

When Sen. Orrin Hatch retires in December, the U.S. Congress will lose the last living link to the lawmakers who collaborated across party lines to transform the FDA into the gold standard for medical product...
Items per page:
1 - 10 of 34